Il2m International Corp (ILIM) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
3500 WEST OLIVE AVENUE BURBANK, CA 91505 |
| State of Incorp. | NV |
| Fiscal Year End | May 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 2/28/2015 MRQ | 5/31/2014 | 5/31/2013 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 834 | 50,036 | |||
| Cash and cash equivalents | 834 | 50,036 | |||
| Receivables | 300 | ||||
| Prepaid expense | 14,835 | ✕ | |||
| Other current assets | 31,612 | ✕ | |||
| Other undisclosed current assets | (46,447) | ||||
| Total current assets: | 834 | 50,336 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 46,566 | ||||
| Other undisclosed noncurrent assets | 31,612 | 9,141 | |||
| Total noncurrent assets: | 78,178 | 9,141 | |||
| TOTAL ASSETS: | 79,012 | 59,477 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 240,269 | 41,422 | |||
| Interest and dividends payable | 1,845 | ||||
| Other undisclosed accounts payable and accrued liabilities | 238,424 | 41,422 | |||
| Debt | 101,370 | 100 | |||
| Deferred revenue and credits | 1,606 | ||||
| Due to related parties | 26,544 | ||||
| Other undisclosed current liabilities | 13,091,725 | ||||
| Total current liabilities: | 13,461,514 | 41,522 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 52,500 | ||||
| Long-term debt, excluding current maturities | 52,500 | ||||
| Liabilities, other than long-term debt | 38,389 | ||||
| Deferred revenue and credits | 38,389 | ||||
| Total noncurrent liabilities: | 38,389 | 52,500 | |||
| Total liabilities: | 13,499,903 | 94,022 | |||
| Equity | |||||
| Equity, attributable to parent, including: | (13,420,891) | (34,545) | |||
| Common stock | 18,051 | 709 | |||
| Additional paid in capital | 4,064,896 | 253,493 | |||
| Accumulated deficit | (17,503,838) | ||||
| Other undisclosed equity, attributable to parent | (288,747) | ||||
| Total equity: | (13,420,891) | (34,545) | |||
| TOTAL LIABILITIES AND EQUITY: | 79,012 | 59,477 | |||
Income Statement (P&L) (USD)
| 2/28/2015 TTM | 5/31/2014 | 5/31/2013 | ||
|---|---|---|---|---|
| Revenues (Revenue, Net) | 50 | |||
| Gross profit: | 50 | |||
| Operating expenses | (112,274) | |||
| Operating loss: | (112,224) | |||
| Interest and debt expense | (323) | |||
| Loss from continuing operations: | (112,547) | |||
| Loss before gain (loss) on sale of properties: | (112,547) | |||
| Net loss available to common stockholders, diluted: | (112,547) | |||
Comprehensive Income (USD)
| 2/28/2015 TTM | 5/31/2014 | 5/31/2013 | ||
|---|---|---|---|---|
| Net loss: | (112,547) | |||
| Comprehensive loss, net of tax, attributable to parent: | (112,547) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.